Page 175 - Read Online

Page 12 of 13 Nag et al. J Cancer Metastasis Treat 2020;6:16 I http://dx.doi.org/10.20517/2394-4722.2020.23

28. Ramachandran S, Haddad D, Li C, Le MX, Ling AK, et al. The SAGA Deubiquitination Module Promotes DNA Repair and Class Switch
Recombination through ATM and DNAPK-Mediated gammaH2AX Formation. Cell Rep 2016;15:1554-65.
29. Armour SM, Bennett EJ, Braun CR, Zhang XY, McMahon SB, et al. A high-confidence interaction map identifies SIRT1 as a mediator of
acetylation of USP22 and the SAGA coactivator complex. Mol Cell Biol 2013;33:1487-502.
30. Young MJ, Hsu KC, Lin TE, Chang WC, Hung JJ. The role of ubiquitin-specific peptidases in cancer progression. J Biomed Sci
2019;26:42.
31. Zhang Y, Yao L, Zhang X, Ji H, Wang L, et al. Elevated expression of USP22 in correlation with poor prognosis in patients with invasive
breast cancer. J Cancer Res Clin Oncol 2011;137:1245-53.
32. Daniel JA, Grant PA. Multi-tasking on chromatin with the SAGA coactivator complexes. Mutat Res 2007;618:135-48.
33. Koehler C, Bonnet J, Stierle M, Romier C, Devys D, et al. DNA binding by Sgf11 protein affects histone H2B deubiquitination by Spt-
Ada-Gcn5-acetyltransferase (SAGA). J Biol Chem 2014;289:8989-99.
34. Henry KW, Wyce A, Lo WS, Duggan LJ, Emre NC, et al. Transcriptional activation via sequential histone H2B ubiquitylation and
deubiquitylation, mediated by SAGA-associated Ubp8. Genes Dev 2003;17:2648-63.
35. Henry KW, Berger SL. Trans-tail histone modifications: wedge or bridge? Nat Struct Biol 2002;9:565-6.
36. Zhao Y, Lang G, Ito S, Bonnet J, Metzger E, et al. A TFTC/STAGA module mediates histone H2A and H2B deubiquitination, coactivates
nuclear receptors, and counteracts heterochromatin silencing. Mol Cell 2008;29:92-101.
37. Ao N, Liu Y, Feng H, Bian X, Li Z, et al. Ubiquitin-specific peptidase USP22 negatively regulates the STAT signaling pathway by
deubiquitinating SIRT1. Cell Physiol Biochem 2014;33:1863-75.
38. Lin Z, Yang H, Kong Q, Li J, Lee SM, et al. USP22 antagonizes p53 transcriptional activation by deubiquitinating Sirt1 to suppress cell
apoptosis and is required for mouse embryonic development. Mol Cell 2012;46:484-94.
39. Kobayashi T, Iwamoto Y, Takashima K, Isomura A, Kosodo Y, et al. Deubiquitinating enzymes regulate Hes1 stability and neuronal
differentiation. FEBS J 2015;282:2411-23.
40. Gao Y, Lin F, Xu P, Nie J, Chen Z, et al. USP22 is a positive regulator of NFATc2 on promoting IL2 expression. FEBS Lett 2014;588:878-
83.
41. Xiao H, Tian Y, Yang Y, Hu F, Xie X, et al. USP22 acts as an oncogene by regulating the stability of cyclooxygenase-2 in non-small cell
lung cancer. Biochem Biophys Res Commun 2015;460:703-8.
42. Wilson MA, Koutelou E, Hirsch C, Akdemir K, Schibler A, et al. Ubp8 and SAGA regulate Snf1 AMP kinase activity. Mol Cell Biol
2011;31:3126-35.
43. Kim D, Hong A, Park HI, Shin WH, Yoo L, et al. Deubiquitinating enzyme USP22 positively regulates c-Myc stability and tumorigenic
activity in mammalian and breast cancer cells. J Cell Physiol 2017;232:3664-76.
44. Atanassov BS, Dent SY. USP22 regulates cell proliferation by deubiquitinating the transcriptional regulator FBP1. EMBO Rep
2011;12:924-30.
45. Li C, Irrazabal T, So CC, Berru M, Du L, et al. The H2B deubiquitinase Usp22 promotes antibody class switch recombination by
facilitating non-homologous end joining. Nat Commun 2018;9:1006.
46. Xiong J, Che X, Li X, Yu H, Gong Z, et al. Cloning and characterization of the human USP22 gene promoter. PLoS One 2012;7:e52716.
47. Xiong J, Zhou X, Gong Z, Wang T, Zhang C, et al. PKA/CREB regulates the constitutive promoter activity of the USP22 gene. Oncol
Rep 2015;33:1505-11.
48. Gennaro VJ, Stanek TJ, Peck AR, Sun Y, Wang F, et al. Control of CCND1 ubiquitylation by the catalytic SAGA subunit USP22 is
essential for cell cycle progression through G1 in cancer cells. Proc Natl Acad Sci U S A 2018;115:E9298-307.
49. Piao S, Liu Y, Hu J, Guo F, Ma J, et al. USP22 is useful as a novel molecular marker for predicting disease progression and patient
prognosis of oral squamous cell carcinoma. PLoS One 2012;7:e42540.
50. Hu J, Liu YL, Piao SL, Yang DD, Yang YM, et al. Expression patterns of USP22 and potential targets BMI-1, PTEN, p-AKT in non-
small-cell lung cancer. Lung Cancer 2012;77:593-9.
51. Yang M, Liu YD, Wang YY, Liu TB, Ge TT, et al. Ubiquitin-specific protease 22: a novel molecular biomarker in cervical cancer
prognosis and therapeutics. Tumour Biol 2014;35:929-34.
52. Wang A, Ning Z, Lu C, Gao W, Liang J, et al. USP22 induces cisplatin resistance in lung adenocarcinoma by regulating gammaH2AX-
mediated DNA damage repair and Ku70/Bax-mediated apoptosis. Front Pharmacol 2017;8:274.
53. Liu YL, Yang YM, Xu H, Dong XS. Aberrant expression of USP22 is associated with liver metastasis and poor prognosis of colorectal
cancer. J Surg Oncol 2011;103:283-9.
54. Lang G, Bonnet J, Umlauf D, Karmodiya K, Koffler J, et al. The tightly controlled deubiquitination activity of the human SAGA complex
differentially modifies distinct gene regulatory elements. Mol Cell Biol 2011;31:3734-44.
55. Zhang K, Yang L, Wang J, Sun T, Guo Y, et al. Ubiquitin-specific protease 22 is critical to in vivo angiogenesis, growth and metastasis of
non-small cell lung cancer. Cell Commun Signal 2019;17:167.
56. Lin Z, Tan C, Qiu Q, Kong S, Yang H, et al. Ubiquitin-specific protease 22 is a deubiquitinase of CCNB1. Cell Discov 2015;1.
57. Ma Y, Fu HL, Wang Z, Huang H, Ni J, et al. USP22 maintains gastric cancer stem cell stemness and promotes gastric cancer progression
by stabilizing BMI1 protein. Oncotarget 2017;8:33329-42.
58. Qiu GZ, Liu Q, Wang XG, Xu GZ, Zhao T, et al. Hypoxia-induced USP22-BMI1 axis promotes the stemness and malignancy of glioma
stem cells via regulation of HIF-1alpha. Life Sci 2020;247:117438.
59. Ning J, Zhang J, Liu W, Lang Y, Xue Y, et al. Overexpression of ubiquitin-specific protease 22 predicts poor survival in patients with
early-stage non-small cell lung cancer. Eur J Histochem 2012;56:e46.